CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 60 enrolled
Drug / intervention
mirtazapine +1 moredrug
Likely dose
mirtazapine 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00497081
NCT00497081Phase 2Completed
CompareCT.gov

Mirtazapine to Reduce Methamphetamine Use Among MSM With High-risk HIV Behaviors

San Francisco Department of Public Health·interventional·Posted Jul 6, 2007·Updated Jan 5, 2015

In Brief

A Phase 2 clinical trial evaluating mirtazapine and placebo for Substance Abuse and HIV Infections. Completed, enrolled 60 participants across 1 site.

Detailed Summary

Studies demonstrate that methamphetamine (meth) use is associated with high-risk sexual behavior among MSM, putting meth-using MSM at extraordinarily high risk for transmitting or acquiring HIV. This study of intermediate size (60 participants) and length (3 months of follow-up) will assess the efficacy of mirtazapine in reducing methamphetamine use among high-risk MSM.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSubstance Abuse, HIV Infections
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA), Public Health Foundation Enterprises, Inc.

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 6, 2007
Enrollment StartMay 1, 2007
Primary CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 19.0 years ago

Interventions

mirtazapinedrug

mirtazapine 30 mg daily for 3 months

placebodrug

placebo 30 mg daily for 3 months